Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BC-819 + BCG solution |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BC-819 | BC819|BC 819|Inodiftagene vixteplasmid | BC-819 (Inodiftagene vixteplasmid) is a recombinant DNA construct encoding an engineered diphtheria toxin that is specifically toxic to bladder cancer cells (Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 499-499). | ||
BCG solution | TICE BCG solution | Bacillus Calmette-Guerin solution | TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|